GLP-1 & compounded medication availability in Louisiana (2026)
Louisiana sits in the middle of the pack: no medication-specific rulebook, but a pharmacy-enforcement record showing its regulators act when compounding is done wrong, and the 2023 semaglutide-sodium cases below are the proof. Here is what actually ships to Louisiana addresses across all ten product lines we track, with the primary document cited.
What ships to Louisiana: all ten lines
| Product line | Available in Louisiana? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Compounded from the base form of semaglutide. The 2023 cases here turned on salt forms, cited below. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Same national price at every dose, Louisiana included. |
| NAD+ | Yes | 8–10 business days | Fulfilled by licensed partner pharmacies. |
| Sermorelin | Yes | 8–10 business days | Ordered through the same longevity flow. |
| Glutathione | No | N/A | Not something OrderlyMeds offers today. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable; its federal record is below. |
| TB-500 | Yes | 8–10 business days | Compounded injectable. Read its section below. |
| KPV | No | N/A | Not carried, since our peptide lines are injectables only. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; the federal picture is below. |
| MOTS-c | Yes | 8–10 business days | Compounded injectable with its own federal record, below. |
A “No” row means exactly that, and an honest gap beats a padded catalog. Louisiana facts on this page were last reviewed on November 16, 2026.
Research peptides in Louisiana: BPC-157, TB-500, KPV, Epitalon & MOTS-c
Four of these five are in the OrderlyMeds formulary for Louisiana: BPC-157, TB-500, Epitalon and MOTS-c, each compounded as an injectable. KPV is not, because our peptide lines are injectable-form only. Each section below states that line’s own federal record, the FDA evaluation history and the current compounding pathway, and states it whether or not the line ships to you.
BPC-157 in Louisiana
OrderlyMeds fills BPC-157 for Louisiana addresses as a compounded injectable on a patient-specific prescription. Both federal facts below apply to every order.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Louisiana
Available to Louisiana as a compounded injectable, patient-specific prescription required. Its federal record is below.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Louisiana
Not shipped to Louisiana or anywhere else: our peptide lines are compounded as injectables, and KPV is not among them.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Louisiana
In the formulary for Louisiana as a compounded injectable. The federal facts below are unchanged by geography.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Louisiana
Ships to Louisiana as a compounded injectable on a patient-specific prescription. Its federal record below is its own, not a copy of the other four.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Louisiana’s pharmacy regulators have actually done
Louisiana has no medication-specific rulebook for the lines on this page, but its regulators have shown exactly where their line sits, with real fines, on the public record. The three cited positions below shape what reaches a Louisiana address.
At its August 16, 2023 meeting, the Louisiana Board of Pharmacy fined a Baton Rouge compounding pharmacy $35,700 plus costs for dispensing 2,380 prescriptions using non-FDA-approved semaglutide sodium, and placed the pharmacy’s owner on a stayed one-year license suspension with probation — actions recorded in the board’s October 2023 newsletter, which the board treats as an official instrument of notification. Source: Louisiana Board of Pharmacy — October 2023 newsletter (PDF).
A pharmacy located outside Louisiana must hold a pharmacy permit from the Louisiana Board of Pharmacy before dispensing prescriptions to patients in the state, and a pharmacy preparing compounded sterile preparations also holds a separate compounded sterile preparations permit, renewed annually. Source: Louisiana Board of Pharmacy.
Louisiana permits prescriptions issued on the basis of a telehealth encounter with a Louisiana-licensed provider, within each licensing board’s scope-of-practice rules; the Center for Connected Health Policy catalogs the state’s current telehealth prescribing policy. Source: CCHP Policy Finder — Louisiana.
In practice, a Louisiana order looks like every other OrderlyMeds order: an online eligibility check, an evaluation by a Louisiana-licensed provider, and fulfillment by a pharmacy permitted for Louisiana. The 2023 cases above turned on a specific ingredient choice, semaglutide sodium, a salt form, and the compounded semaglutide dispensed today uses the base form, prescribed patient by patient. Pricing is national: the price on our pricing page is the Louisiana price.
Louisiana availability FAQs
Is compounded semaglutide available in Louisiana?
Yes. OrderlyMeds ships base-form compounded semaglutide to Louisiana addresses under patient-specific prescriptions. New customers start at $74/month for the first two months.
What were Louisiana's 2023 semaglutide cases about?
A specific ingredient choice: semaglutide sodium, a salt form, rather than the base form used in the FDA-approved products. The cited section above records the fine and the newsletter that documents it.
Do I need an in-person visit to get started in Louisiana?
No. A telemedicine evaluation by a Louisiana-licensed provider is how OrderlyMeds works here. The regulator section above cites the state's telehealth prescribing policy.
How long does delivery to Louisiana take?
Our published window is 8–10 business days from signup, to any Louisiana address.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
